US 6,982,262 B2
Combination of cyamemazine and an atypical neuroleptic
Michel Dib, Paris (France); and Cyrille Leperlier, Fontainebleau (France)
Assigned to Aventis Pharma S. A., Antony (France)
Filed on Feb. 20, 2004, as Appl. No. 10/783,451.
Application 10/783451 is a continuation of application No. 10/164771, filed on Jun. 07, 2002, granted, now 6,720,318.
Application 10/164771 is a continuation of application No. PCT/FR00/03446, filed on Dec. 08, 2000, abandoned.
Claims priority of application No. 99 15632 (FR), filed on Dec. 10, 1999.
Prior Publication US 2004/0167125 A1, Aug. 26, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A61K 31/496 (2006.01); A61K 31/454 (2006.01)
U.S. Cl. 514—226.2 20 Claims
 
1. A pharmaceutical composition comprising at least about 50 mg to about 600 mg of cyamemazine in combination with an atypical neuroleptic selected from the group consisting of sertindole, quetiapine and ziprasidone or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier.